Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q4 2023 Earnings Call Transcript

Page 4 of 4

Q – Unidentified Analyst: Thanks so much.

Chris Peetz: Thanks for the questions

Operator: Thank you. There are no additional questions at this time. I will pass it back to Chris Peetz for any closing remarks.

Chris Peetz: Great. Thanks again for everyone for joining us for today. Before ending the call, I do want to put a plug-in for Rare Disease Day tomorrow, today to build awareness for the more than 7,000 rare diseases impacting patients around the world and celebrate some of the meaningful advances in research that we’ve seen in recent years. Tomorrow, as part of Rare Disease Day, we’re excited to be able to share a manuscript published in hepatology, featuring long-term data in patients with Alagille syndrome treated with LIVMARLI. So, please join us in supporting the many advocacy groups that passionately lead efforts to support patients in research and rare disease tomorrow and have a great evening. Goodbye.

Operator: That concludes today’s conference call. Thank you. You may now disconnect your line.

Follow Mirum Pharmaceuticals Inc. (NASDAQ:MIRM)

Page 4 of 4